In that case, T cell lymphoma developed after 20 months of treatment using pembrolizumab, and lymphoma cells expressed CD4+ CD8+, with a slight predominance of CD8+ cells. The gene discussed is CD8A; the disease is T-cell non-Hodgkin lymphoma.